<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Txt>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE334nnn/GSE334585/suppl/GSE334585_all_samples_FeatureCount_count.txt.gz</Txt><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE334nnn/GSE334585/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE334585</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>iNOS is a key mediator of anti-PD-1 melanoma therapy response</name><description>Background: Inducible nitric oxide synthase (iNOS) and its product nitric oxide (NO) were historically linked to poor melanoma outcomes, yet recent evidence shows NO supports anti-tumor immunity. This study examines how iNOS shapes anti–PD-1 efficacy, particularly through interferon signaling. Methods: B16 D5 melanoma tumors were implanted in wild-type (WT) and iNOS knockout (KO) mice to compare tumor growth and response to anti–PD-1 therapy. Flow cytometry, apoptosis assays, and RNA sequencing assessed NO production, PD-L1 expression, and interferon-related gene activation. In vitro, melanoma cells were treated with NO donors (DETA NONOate, SNAP) to assess proliferation and apoptosis. Peripheral blood mononuclear cells from 27 melanoma patients receiving anti–PD-1 therapy were analyzed with multiparameter flow cytometry to correlate NO-associated immune subsets with progression-free survival (PFS). Results: Tumors grew significantly faster in iNOS KO mice, and anti–PD-1 therapy had no effect, demonstrating that iNOS-derived NO contributes to treatment efficacy. NO donors inhibited melanoma proliferation and induced apoptosis in vitro. Transcriptomic analysis showed anti–PD 1 upregulated interferon pathway genes (STAT1, IRF1, IFNB1) in WT but not iNOS KO mice. In patients, a NO-producing dendritic cell subset (DAF FM⁺CD11c⁺) was associated with improved PFS (hazard ratio 0.453; 95% CI=0.270-0.992; p = 0.048), indicating a NO-dependent enhancement of interferon-driven immune activity.</description><dates><publication>2026/07/15</publication></dates><accession>GSE334585</accession><cross_references><GSM>GSM9791337</GSM><GSM>GSM9791315</GSM><GSM>GSM9791316</GSM><GSM>GSM9791338</GSM><GSM>GSM9791339</GSM><GSM>GSM9791317</GSM><GSM>GSM9791318</GSM><GSM>GSM9791319</GSM><GSM>GSM9791340</GSM><GSM>GSM9791341</GSM><GSM>GSM9791342</GSM><GSM>GSM9791320</GSM><GSM>GSM9791343</GSM><GSM>GSM9791321</GSM><GSM>GSM9791322</GSM><GSM>GSM9791344</GSM><GSM>GSM9791345</GSM><GSM>GSM9791323</GSM><GSM>GSM9791346</GSM><GSM>GSM9791324</GSM><GSM>GSM9791325</GSM><GSM>GSM9791347</GSM><GSM>GSM9791348</GSM><GSM>GSM9791326</GSM><GSM>GSM9791349</GSM><GSM>GSM9791327</GSM><GSM>GSM9791328</GSM><GSM>GSM9791306</GSM><GSM>GSM9791329</GSM><GSM>GSM9791307</GSM><GSM>GSM9791308</GSM><GSM>GSM9791309</GSM><GSM>GSM9791350</GSM><GSM>GSM9791351</GSM><GSM>GSM9791330</GSM><GSM>GSM9791352</GSM><GSM>GSM9791353</GSM><GSM>GSM9791331</GSM><GSM>GSM9791310</GSM><GSM>GSM9791332</GSM><GSM>GSM9791333</GSM><GSM>GSM9791311</GSM><GSM>GSM9791334</GSM><GSM>GSM9791312</GSM><GSM>GSM9791313</GSM><GSM>GSM9791335</GSM><GSM>GSM9791336</GSM><GSM>GSM9791314</GSM><GPL>24247</GPL><GSE>334585</GSE><taxon>Mus musculus</taxon><PMID>[42440610]</PMID></cross_references></HashMap>